Latest News - Thermo Fisher Scientific
Top Corporates Hub
Thermo Fisher Scientific
[Latest] Global Bioprocess Automation Software Market Size/Share Worth USD 6.19 Billion by 2035 at a 14 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
26.05.2026 04:30
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Bioprocess Automation Software Market size & share revenue was valued at approximately USD 1.67 Billion in 2025 and is expected to reach USD 1.90 Billion in 2026 and is expected to reach around USD 6.19 Billion by 2035, at a CAGR of 14 between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Xeris Pharmaceuticals
Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day
20.05.2026 12:30
WALTHAM, Mass., May 20, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, hosted its Investor Day today. Chairman and Chief Executive Officer Marc N. Casper and members of the senior leadership team highlighted the company’s industry leadership and the essential role of its best-in-class products and services to customers around the world.
1 S&P 500 Stock with Promising Prospects and 2 We Ignore
20.05.2026 09:24
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Global Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG
19.05.2026 10:39
According to the latest market analysis by Future Market Insights (FMI), the global Cell Culture Media Market is projected to grow from USD 3.7 billion in 2026 to USD 7.1 billion by 2036, expanding at a CAGR of 6.6% during the forecast period. Market growth is being driven by rising biologics production, expanding cell and gene therapy pipelines, increasing adoption of serum-free formulations, and growing demand for reproducible, GMP-grade manufacturing inputs across regulated biopharmaceutical
Thermo Fisher Deepens Oncology Role With Ibtrozi Manufacturing Milestone
18.05.2026 04:29
Thermo Fisher Scientific (NYSE:TMO) has completed technology transfer and product introduction for Ibtrozi, a treatment for ROS1-positive non-small cell lung cancer. This marks a key milestone in its collaboration with Nuvation Bio and reflects a deeper role in biopharma manufacturing and oncology drug commercialization. For investors watching NYSE:TMO, this update highlights the company’s position as a partner for complex drug production in cancer care, not just a supplier of equipment and...
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know
17.05.2026 09:40
A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with service-sector prices rising at their fastest pace in four years.
Thermo Fisher Scientific : Additional Soliciting Materials
11.05.2026 12:09
THERMO FISHER SCIENTIFIC INC. Supplemental Information Regarding Proposal 2: Advisory Vote to Approve Executive Compensation Commencing on May 11, 2026, Thermo...
Is It Time To Revisit Thermo Fisher Scientific (TMO) After This Year’s Share Price Pullback
07.05.2026 01:16
Wondering if Thermo Fisher Scientific at around US$472.95 is offering good value right now, or if the stock has already run ahead of itself. The share price has been mixed recently, with a 1.4% gain over the last 7 days, a 3.1% decline over the last 30 days, and a 20.2% decline year to date, even though the 1 year return sits at 16.4%. These moves come against a backdrop of ongoing attention on Thermo Fisher Scientific as a major supplier of life sciences tools and services, with investors...
Lateral Flow Assay Market: 2026 Research Report - AI and Digital Technology Integration to Propel Lateral Flow Assay Market Expansion - Forecast to 2030
06.05.2026 13:15
The global lateral flow assay (LFA) market is projected to grow from USD 10.01 billion in 2024 to USD 15.42 billion by 2030, driven by increasing demand for point-of-care testing and the rising prevalence of infectious diseases. The LFA market encompasses the development, manufacturing, and distribution of test kits and related products across healthcare, pharmaceuticals, food safety, and more. Segmented by product type, applications, technology, and end-users, the market thrives on advancements
Thermo Fisher Scientific’s Clinical Research Business Named a Leader Among CROs in 2026 ISG Provider Lens™ Report for Use of AI in Clinical Trials
06.05.2026 12:30
WALTHAM, Mass., May 06, 2026--Thermo Fisher Scientific Inc., the world leader in serving science, earned a Leader designation among contract research organizations (CROs) in the 2026 ISG Provider Lens™ Life Sciences Digital Services report, underscoring the company’s continued investment in digital innovation across the clinical development continuum.
Billionaire Investor Takes New Stake In Thermo Fisher Scientific
01.05.2026 16:31
Hedge fund billionaire Daniel Loeb assumed a stake in the Life Sciences Tools & Services company Thermo Fisher Scientific Inc at Third Point LLC in the fourth quarter of FY25. As of Dec. 31, 2025, Loeb bought 50,000 shares in the company. Recent Key Events In February, Thermo Fisher Scientific’s Board approved a quarterly dividend of $0.47 per share, payable on April 15, 2026, to shareholders of record as of March 13, 2026. The new dividend represents a 10% increase from the prior $0.43 payout.
1 Profitable Stock with Impressive Fundamentals and 2 Facing Headwinds
29.04.2026 02:04
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Thermo Fisher selling microbiology business to Astorg for $1.08B
27.04.2026 14:38
The unit generated $645 million in revenue in 2025 and supplies products used in clinical, pharmaceutical, and food safety testing
Thermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg
27.04.2026 12:00
WALTHAM, Mass., April 27, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has signed a definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note.
Astorg III, FCPR, managed by Astorg Asset Management S A.R.L. signed a definitive agreement to acquire Global Microbiology Business from Thermo Fisher Scientific Inc. for approximately $1.1 billion.
27.04.2026 10:20
Astorg III, FCPR, managed by Astorg Asset Management S A.R.L. signed a definitive agreement to acquire Global Microbiology Business from Thermo Fisher Scientific Inc. for approximately $1.1 billion...
Thermo Fisher to Sell Microbiology Business to Astorg for About $1.075 Billion
27.04.2026 08:53
By Colin Kellaher Thermo Fisher Scientific has struck a deal to sell its microbiology business to European private-equity firm Astorg for about $1.075 billion. Thermo Fisher on Monday said...
Thermo Fisher to sell microbiology business to PE firm Astorg for over $1 billion
27.04.2026 08:34
Medical equipment maker Thermo Fisher Scientific said on Monday it would sell its microbiology business to private equity firm Astorg for about $1.08 billion. o Deal consists of cash...
Thermo Fisher to sell its microbiology business to Astorg for about $1.08 billion
27.04.2026 08:08
Thermo Fisher Scientificsaid on Monday it has agreed to sell its microbiology businessto a pan-European private equity firm Astorg for about $1.08billion, consisting of cash and a $50 million...
Thermo Fisher Scientific (TMO) Announces Fiscal Q1 2026 Results
27.04.2026 05:54
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the best stem cell therapy stocks to buy. On April 23, Thermo Fisher Scientific Inc. (NYSE:TMO) announced financial results for fiscal Q1 2026. Revenue for the quarter rose 6% to $11.01 billion, compared to $10.36 billion in the same quarter last year. Organic revenue underwent a 1% growth. […]